APPLICATION METHOD OF POTASSIUM ION CHANNEL BLOCKER IN PREPARATION OF DRUGS FOR TREATING LIVER FIBROSIS
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Nov 28, 2024
app pub date -
Jul 6, 2023
filing date -
Jul 6, 2023
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
An application of potassium ion (K+) channel blocker in preparation of drugs for treating liver fibrosis is provided, which relates to the field of medical technologies. The K+ channel blocker is sotalol, the sotalol is originally used as an antiarrhythmic drug in clinic and has a property of inhibiting K+ channels. Experiments show that sotalol can effectively inhibit liver fibrosis and reduce expression of fibrosis-related protein alpha-smooth muscle actin (α-SMA), specifically by regulating expression and/or function of autophagy and epithelial-mesenchymal transition (EMT) molecules to achieve inhibition of hepatic stellate cell (HSC) fibrosis, so as to provide a new drug choice for clinical treatment of the liver fibrosis.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully